Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS

Renaissance Technologies LLC lowered its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS) by 23.4% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 453,482 shares of the company’s stock after selling 138,204 shares during the quarter. Renaissance Technologies LLC owned about 2.29% of Keros Therapeutics worth $5,006,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. Financial Management Professionals Inc. bought a new stake in shares of Keros Therapeutics during the 4th quarter valued at $29,000. Caitong International Asset Management Co. Ltd raised its stake in Keros Therapeutics by 254.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after purchasing an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares in the last quarter. New York State Common Retirement Fund lifted its position in Keros Therapeutics by 264.1% during the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock worth $142,000 after purchasing an additional 7,700 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Keros Therapeutics by 8.6% during the second quarter. The Manufacturers Life Insurance Company now owns 12,451 shares of the company’s stock worth $166,000 after buying an additional 988 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, Director Nima Farzan sold 2,625 shares of Keros Therapeutics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $10.73, for a total transaction of $28,166.25. Following the transaction, the director directly owned 9,767 shares of the company’s stock, valued at approximately $104,799.91. The trade was a 21.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Alpna Seth sold 2,625 shares of the company’s stock in a transaction dated Thursday, June 4th. The shares were sold at an average price of $10.72, for a total value of $28,140.00. Following the completion of the sale, the director owned 9,767 shares in the company, valued at $104,702.24. This trade represents a 21.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 8,425 shares of company stock worth $89,994. Company insiders own 12.60% of the company’s stock.

Keros Therapeutics Trading Up 6.6%

NASDAQ:KROS opened at $10.65 on Friday. The stock’s 50-day moving average is $10.62 and its 200-day moving average is $12.40. Keros Therapeutics, Inc. has a 1-year low of $9.69 and a 1-year high of $22.55. The stock has a market cap of $211.19 million, a P/E ratio of -2.88 and a beta of 0.99.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Monday, August 3rd. The company reported ($1.45) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. As a group, equities analysts forecast that Keros Therapeutics, Inc. will post -4.96 EPS for the current year.

More Keros Therapeutics News

Here are the key news stories impacting Keros Therapeutics this week:

• Positive Sentiment: Wells Fargo initiated a Buy rating on Keros Therapeutics, adding a new bullish opinion that may be helping investor sentiment. Wells Fargo Issues a Buy Rating on Keros Therapeutics
• Positive Sentiment: HC Wainwright maintained its Buy rating and $20 price target while raising its FY2026 EPS forecast to a loss of $4.62 from a loss of $5.12. The improved estimate is favorable relative to the firm’s prior outlook and supports the broader bullish analyst view. HC Wainwright Keros Therapeutics analyst estimates
• Neutral Sentiment: Analysts continue to describe Keros Therapeutics as attractive among healthcare stocks, but the company remains unprofitable, with a negative earnings outlook and substantial dependence on future clinical and commercial progress. Analysts Are Bullish on Top Healthcare Stocks
• Negative Sentiment: HC Wainwright lowered its Q4 2026 EPS forecast to a loss of $1.49 from $1.33 and reduced estimates for FY2027 through FY2030. The cuts imply larger expected losses in those years, despite the unchanged Buy rating and $20 target. HC Wainwright revised Keros Therapeutics earnings estimates
• Negative Sentiment: Leerink Partners lowered its Keros Therapeutics price target to $23. The target remains well above recent trading levels, but the reduction signals a more cautious valuation assessment. Leerink Partners Lowers Keros Therapeutics Price Target

Analyst Ratings Changes

A number of analysts have recently weighed in on KROS shares. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Leerink Partners cut their target price on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating for the company in a research note on Tuesday. Zacks Research lowered Keros Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, July 29th. Wells Fargo & Company lowered their price target on Keros Therapeutics from $20.00 to $18.00 and set an “overweight” rating for the company in a report on Tuesday. Finally, Weiss Ratings lowered Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Four investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Keros Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $20.50.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-?) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.